# J. Gene Wang

> J. Gene Wang is a physician-scientist and the founder and CEO of Immetas Therapeutics, a biotech he co-founded in 2018 with Harvard's David Sinclair to attack the chronic, low-grade inflammation that drives aging and age-related cancers. Trained with an M.D. from Peking University and a Ph.D. in immunobiology from Yale, Wang spent roughly two decades inside Merck, Abbott, GSK, and Novartis, where he helped move blockbuster drugs like Humira, Gardasil, Zolinza, and Varubi from lab bench to patients. At Immetas he is engineering bispecific antibodies designed to retune inflammation inside the tumor microenvironment and break resistance to checkpoint immunotherapy, backed by an $11M Series A from Morningside Ventures.

- **Role:** Founder & CEO at Immetas Therapeutics
- **Organizations:** Immetas Therapeutics, Merck, Abbott, GSK, Novartis, Yale University
- **Nationality:** American
- **Education:** M.D., Peking University Medical Center, Ph.D. in Immunobiology (T lymphocyte co-stimulation), Yale University, Medical residency, Yale New Haven Hospital
- **Known for:** Co-founded Immetas Therapeutics to target inflammation pathways in aging, Helped advance clinical development of Humira (adalimumab), Helped advance clinical development of Gardasil (HPV vaccine)

## Career timeline

- **~2000s-2010s** — Held drug development roles at Abbott, GSK, and Novartis in immunology/inflammation
- **~2010s** — Led oncology drug development at Merck
- **2018** — Co-founded Immetas Therapeutics with David Sinclair in October 2018
- **2020** — Closed $11M Series A led by Morningside Ventures

## Achievements

- Co-founded Immetas Therapeutics to target inflammation pathways in aging
- Helped advance clinical development of Humira (adalimumab)
- Helped advance clinical development of Gardasil (HPV vaccine)
- Helped advance clinical development of Zolinza (vorinostat)
- Helped advance clinical development of Varubi (rolapitant)
- Steered multiple first-in-class compounds from discovery to clinical proof-of-concept
- Raised $11M Series A from Morningside Ventures (2020)

## Latest updates

- **2020-09** — Immetas announced an $11M Series A financing led by Morningside Ventures to advance its inflammaging research.

## Links

- Website: https://immetas.com
- LinkedIn: http://www.linkedin.com/in/j-gene-wang-m-d-ph-d-2856045

---

Profile page: https://yespress.io/gene-wang
Published by YesPress — https://yespress.io
Last updated: 2026-06-12